Stocklytics Platform
Asset logo for symbol FATE
Fate Therapeutics
FATE55
$1.68arrow_drop_up1.80%$0.03
Penny Stock
Asset logo for symbol FATE
FATE55

$1.68

arrow_drop_up1.80%

Performance History

Chart placeholder
Key Stats
Open$1.67
Prev. Close$1.66
EPS-1.64
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$191.34M
PE Ratio-
LOWHIGH
Day Range1.64
1.80
52 Week Range1.59
8.83
Ratios
EPS-1.64

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Fate Therapeutics (FATE)

Fate Therapeutics Inc (FATE) is a biopharmaceutical company that focuses on the development of programmed cellular immunotherapies for cancer and immune disorders. The company utilizes its proprietary induced pluripotent stem cell (iPSC) product platform to engineer cell-based therapies. These therapies are designed to harness the power of the immune system to target and eliminate cancer cells. Fate Therapeutics' lead product candidate, FATE-NK100, is an off-the-shelf natural killer (NK) cell cancer immunotherapy that has shown promising results in preclinical studies. The company is also developing other cell-based candidates, including FATE-NK100+IL-15, for the treatment of hematologic malignancies and solid tumors.
Fate Therapeutics Inc was founded in 2007 and is headquartered in San Diego, California. The company's stock symbol is FATE and it is listed on the NASDAQ exchange. As of DATE, Fate Therapeutics has a market capitalization of MARKET_CAP. The company's stock price has experienced fluctuations over the past year, with a 52-week range of LOW_PRICE - HIGH_PRICE. The stock is currently trading at DAY_RANGE, with a trading volume of TRADING_VOLUME shares. Fate Therapeutics' stock analysis indicates that it may be a promising investment opportunity, with a favorable PEG ratio compared to the industry average. Investors interested in the company can find further information in the latest news and updates regarding Fate Therapeutics' stock performance and future prospects.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. J. Scott Wolchko
Headquarters
San Diego
Employees
551
Exchange
NASDAQ
add Fate Therapeutics  to watchlist

Keep an eye on Fate Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Fate Therapeutics 's (FATE) price per share?

The current price per share for Fate Therapeutics (FATE) is $1.68. The stock has seen a price change of $0.03 recently, indicating a 1.81% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Fate Therapeutics (FATE)?

For Fate Therapeutics (FATE), the 52-week high is $8.83, which is 425.6% from the current price. The 52-week low is $1.59, the current price is 5.33% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Fate Therapeutics (FATE) a growth stock?

Fate Therapeutics (FATE) has shown an average price growth of -4.97% over the past three years. It has received a score of -4 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Fate Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Fate Therapeutics (FATE) stock price performance year to date (YTD)?

As of the latest data, Fate Therapeutics (FATE) has a year-to-date price change of -54.47%. Over the past month, the stock has experienced a price change of -18.84%. Over the last three months, the change has been -53.85%. Over the past six months, the figure is -55.32%. Looking at a longer horizon, the five-year price change stands at -91.9%.
help

Is Fate Therapeutics (FATE) a profitable company?

Fate Therapeutics (FATE) has a net income of -$160.93M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.7K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $63.53M, although specific revenue growth data is currently not available. Operating income is noted at -$190.51M. Furthermore, the EBITDA is -$164.67M.
help

What is the market capitalization of Fate Therapeutics (FATE)?

Fate Therapeutics (FATE) has a market capitalization of $191.34M. The average daily trading volume is 1.69, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level